# US 2001/0025039 A1 · Aza- indolyl derivatives for treating obesity

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2001/0025039 A1
- Document ID: US20010025039A1
- Status: Published application
- Kind: A1
- Application number: 09/794,491
- Filed: 2001-02-27
- Published: 2001-09-27
- Earliest claimed: 2000-03-06
- Assignees: Hoffman-La Roche Inc.; Vernalis Research Limited
- Inventors: Jonathan Mark Bentley; Paul Hebeisen; Sven Taylor
- Web page: https://patentgrep.com/patent/US20010025039A1

## CPC

- C07D 471/14: Ortho-condensed systems
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/14: Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 13/00: Drugs for disorders of the urinary system
- A61P 13/02: of urine or of the urinary tract, e.g. urine acidifiers
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/06: Antimigraine agents
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/20: Hypnotics; Sedatives
- A61P 25/22: Anxiolytics
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 25/30: for treating abuse or dependence
- A61P 25/32: Alcohol-abuse
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C07D 487/14: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Novel compounds of formula (I): 1 wherein X1, X2, X3 and X4, n, R1, R2 and R3 are defined in the specification, and pharmaceutically acceptable salts and prodrugs of the compounds of formula (I) have therapeutic uses. These compounds are useful for the treatment of disorders of the central nervous system; damage to the central nervous system; cardiovascular disorders; gastrointestinal disorders; diabetes insipidus, and sleep apnea. They are particularly useful for the treatment of obesity.

## Claims

### Claim 1

An aza-indolyl derivative selected from the group consisting of a compound of formula (I): 18
wherein
n is 1, 2 or 3;
X1 is nitrogen or CR4; X2 is nitrogen or CR5; X3 is nitrogen or CR6; X4 is nitrogen or CR7; wherein one or two of X1, X2, X3 and X4 are nitrogen;
R1, R2 and R3 are independently selected from hydrogen and alkyl;
R4, R5, R6 and R7 are independently selected from hydrogen, halogen, hydroxy, alkyl, aryl, alkoxy, aryloxy, alkylthio, arylthio, alkylsulfonyl, alkylsulfoxyl, arylsulfonyl, arylsulfoxyl, amino, monoalkylamino, dialkylamino, nitro, cyano, carboxaldehyde, alkylcarbonyl, arylcarbonyl, aminocarbonyl, monoalkylaminocarbonyl, dialkylaminocarbonyl, alkoxycarbonylamino, aminocarbonyloxy, monoalkylaminocarbonyloxy, dialkylaminocarbonyloxy, monoalkylaminocarbonylamino and dialkylaminocarbonylamino, and
wherein for each of X1, X2, X3 and X4 which is nitrogen, adjacent ring atoms selected from the group consisting of X1, X2, X3 and X4 are not substituted by halogen;
and pharmaceutically acceptable salts or prodrugs thereof.

### Claim 2 (depends on 1)

The aza-indolyl derivative of claim 1, wherein the compound of formula (I) is in the form of the enantiomer shown in formula (Ia): 19
wherein R1, R2, R3, X1, X2, X3, X4 and n are defined as in claim 1.

### Claim 3 (depends on 1)

The aza-indolyl derivative of claim 1, wherein two of X1, X2, X3 and X4 are nitrogen and these nitrogen atoms are in meta or para position to each other.

### Claim 4 (depends on 1)

The aza-indolyl derivative of claim 1, wherein X1 is nitrogen, X2CR5, X3 is CR6, and X4 is CR7.

### Claim 5 (depends on 1)

The aza-indolyl derivative of claim 1, wherein X1 is CR4; X2 is nitrogen; X3 is CR6 and X4 is CR7.

### Claim 6 (depends on 1)

The aza-indolyl derivative of claim 1, wherein X1 is CR4, X2 is CR5; X3 is nitrogen and X4 is CR7.

### Claim 7 (depends on 1)

The aza-indolyl derivative of claim 1, wherein X1 is CR4; X2 is CR5; X3 is CR6 and X4 is nitrogen.

### Claim 8 (depends on 1)

The aza-indolyl derivative of claim 1, wherein X1 is nitrogen, X2 is CR5; X3 is nitrogen and X4 is CR7.

### Claim 9 (depends on 1)

The aza-indolyl derivative of claim 1, wherein X1 is CR4, X2 is nitrogen, X3 is CR6 and X4 is nitrogen.

### Claim 10 (depends on 1)

The aza-indolyl derivative of claim 1, wherein X1 is nitrogen, X2 is CR5, X3 is CR6 and X4 is nitrogen.

### Claim 11 (depends on 1)

The aza-indolyl derivative of claim 1, wherein n is 1.

### Claim 12 (depends on 1)

The aza-indolyl derivative of claim 1, wherein R1 and R2 are hydrogen.

### Claim 13 (depends on 1)

The aza-indolyl derivative of claim 1, wherein R1 is hydrogen and R2 is alkyl.

### Claim 14 (depends on 1)

The aza-indolyl derivative of claim 1, wherein R1 is hydrogen and R2 is arylalkyl.

### Claim 15 (depends on 1)

The aza-indolyl derivative of claim 1, wherein R3 is methyl.

### Claim 16 (depends on 1)

The aza-indolyl derivative of claim 1, wherein R3 is hydrogen.

### Claim 17 (depends on 1)

The aza-indolyl derivative of claim 1, wherein R4, R5, R6 and R7 are selected from hydrogen, halogen, hydroxy, alkyl, aryl, alkoxy, aryloxy, alkylthio, alkylsulfoxyl and alkylsulfonyl.

### Claim 18 (depends on 1)

The aza-indolyl derivative of claim 1, wherein R4 is hydrogen or halogen.

### Claim 19 (depends on 1)

The aza-indolyl derivative of claim 1, wherein R5 is not hydrogen.

### Claim 20 (depends on 19)

The aza-indolyl derivative of claim 19, wherein R5 is selected from halogen, alkyl, alkoxy and alkylthio.

### Claim 21 (depends on 1)

The aza-indolyl derivative of claim 1, wherein R6 is not hydrogen.

### Claim 22 (depends on 1)

The aza-indolyl derivative of claim 1, wherein R6 is selected from hydrogen and halogen.

### Claim 23 (depends on 1)

The aza-indolyl derivative of claim 1, wherein two or three of R4, R5, R6 and R7 are hydrogen.

### Claim 24 (depends on 1)

The aza-indolyl derivative of claim 1, wherein
n is 1 or 2;
one of X1, X2, X3 and X4 is nitrogen and the remainder are CH; and
R1, R2 and R3are independently selected from hydrogen and lower alkyl.

### Claim 25 (depends on 24)

The aza-indolyl derivative of claim 24, wherein said compound of formula (I) is (S)-2-(2,3-dihydro-1H-3a,5-diaza-cyclopenta[a]inden-8-yl)-1-methyl-ethylamine.

### Claim 26 (depends on 24)

The aza-indolyl derivative of claim 24, wherein said compound of formula (I) is (R)-2-(2,3-dihydro-1H-3a,5-diaza-cyclopenta[a]inden-8-yl)-1-methyl-ethylamine.

### Claim 27 (depends on 24)

The aza-indolyl derivative of claim 24, wherein said compound of formula (I) is (S)-2-(2,3-dihydro-1H-3a,6-diaza-cyclopenta[a]inden-8-yl)-1-methyl-ethylamine.

### Claim 28 (depends on 24)

The aza-indolyl derivative of claim 24, wherein said compound of formula (I) is (R)-2-(2,3-dihydro-1H-3a,6-diaza-cyclopenta[a]inden-8-yl)-1-methyl-ethylamine.

### Claim 29 (depends on 24)

The aza-indolyl derivative of claim 24, wherein said compound of formula (I) is (R)-2-(2,3-dihydro-1H-3a,4-diaza-cyclopenta[a]inden-8-yl)-1-methyl-ethylamine.

### Claim 30 (depends on 24)

The aza-indolyl derivative of claim 24, wherein said compound of formula (I) is (S)-2-(2,3-dihydro-1H-3a,4-diaza-cyclopenta[a]inden-8-yl)-1-methyl-ethylamine.

### Claim 31 (depends on 24)

The aza-indolyl derivative of claim 24, wherein said compound of formula (I) is 2-(2,3-dihydro-1H-3a,6-diaza-cyclopenta[a]inden-8-yl)-ethylamine.

### Claim 32

A method of treating obesity, comprising administering to a patient in need of such treatment an effective dose of an aza-indolyl derivative selected from the group consisting of a compound of formula (I) 20
wherein
n is 1, 2 or 3;
X1 is nitrogen or CR4; X2 is nitrogen or CR5; X3 is nitrogen or CR6; X4 is nitrogen or CR7; wherein one or two of X1, X2, X3 and X4 are nitrogen;
R1, R2 and R3 are independently selected from hydrogen and alkyl;
R4, R5, R6 and R7 are independently selected from hydrogen, halogen, hydroxy, alkyl, aryl, alkoxy, aryloxy, alkylthio, arylthio, alkylsulfonyl, alkylsulfoxyl, arylsulfonyl, arylsulfoxyl, amino, monoalkylamino, dialkylamino, nitro, cyano, carboxaldehyde, alkylcarbonyl, arylcarbonyl, aminocarbonyl, monoalkylaminocarbonyl, dialkylaminocarbonyl, alkoxycarbonylamino, aminocarbonyloxy, monoalkylaminocarbonyloxy, dialkylaminocarbonyloxy, monoalkylaminocarbonylamino and dialkylaminocarbonylamino, and
wherein for each of X1, X2, X3 and X4 which is nitrogen, adjacent ring atoms selected from the group consisting of X1, X2, X3 and X4 are not substituted by halogen;
and pharmaceutically acceptable salts or prodrugs thereof.

### Claim 33 (depends on 32)

The method according to claim 32, wherein said treatment is prophylactic treatment.

### Claim 34 (depends on 32)

The method according to claim 32, further comprising administering to the patient a therapeutically effective amount of a lipase inhibitor.

### Claim 35 (depends on 32)

The method according to claim 32, wherein the lipase inhibitor is orlistat.
